- Decreased understanding of Alnylam's vision for the future among employees (85% favorable responses in 2023 vs. 99% in 2014).
- Data gaps in water usage at some locations.
Alnylam Pharmaceuticals, Inc.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Alnylam Pharmaceuticals, Inc. disclosed greenhouse gas emissions of 13.5K tCO2e/year (Scope 1+2 market-based). By scope: Scope 1: 3.5K tCO2e/year; Scope 2: 9.9K tCO2e/year (market-based); Scope 3: 2.1K tCO2e/year (select categories). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
13.5K tCO2e/year (Scope 1+2 market-based)
2023
Renewable Energy
100% at Norton and Alewife facilities (as of January 2024)
of total energy
Water Usage
15.2 million gallons/year
2023
Waste
505 tons/year (Municipal Solid Waste)
2023
Energy Use
24.6K MWh/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 3.5K tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 9.9K tCO2e/year (market-based) |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 2.1K tCO2e/year (select categories) |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 13.5K tCO2e/year (Scope 1+2 market-based) |
| 2022 | 15.1K tCO2e (2021) |
| 2021 | 11.4K tCO2e/year (2020 baseline) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Sourcing renewable energy for Norton and Alewife facilities, resulting in zero Scope 2 market-based GHG emissions at both sites.
- 7% reduction in water consumption at Norton facility in 2023.
- 27% year-over-year savings in electricity at Zug office due to LED lighting.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Continue Scope 1 and 2 GHG emissions calculation and work toward determining baseline year.
- Increase diverse supplier spend 5% in 2024.
📅 Medium-term
- Achieve Alnylam P5x25 strategy goals (Patients: Over 0.5 million on Alnylam RNAi medicines globally; Products: 6+ marketed products in rare and prevalent diseases; Pipeline: Over 20 clinical programs, with 10+ in late stages and 4+ INDs per year; Performance: ≥40% revenue CAGR through YE 2025; Profitability: Achieve sustainable non-GAAP profitability within the period).
🌱 ESG Focus Areas
PatientsScienceEmployeesCommunitiesPlanetGovernance